{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:39:28Z","timestamp":1778884768045,"version":"3.51.4"},"reference-count":138,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Dual antiplatelet therapy (DAPT), comprising aspirin and a P2Y12 receptor inhibitor, is the cornerstone of post-percutaneous coronary intervention treatment to prevent stent thrombosis and reduce the risk of adverse cardiovascular events. The selection of an optimal DAPT regimen, considering the interplay of various antiplatelet agents, patient profiles, and procedural characteristics, remains an evolving challenge. Traditionally, a standard duration of 12 months has been recommended for DAPT in most patients. While contemporary guidelines provide general frameworks, DAPT modulation with longer or shorter treatment courses followed by aspirin or P2Y12 inhibitor monotherapy are evolving towards an individualized strategy to optimize the balance between efficacy and safety. This review comprehensively examines the current landscape of DAPT strategies after coronary stenting, with a focus on emerging evidence for treatment individualization.<\/jats:p>","DOI":"10.3390\/jcm12227144","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T09:23:43Z","timestamp":1700213023000},"page":"7144","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Individualization of Duration of Dual Antiplatelet Therapy after Coronary Stenting: A Comprehensive, Evidence-Based Review"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8015-5211","authenticated-orcid":false,"given":"Gabriele","family":"Carciotto","sequence":"first","affiliation":[{"name":"Division of Cardiology, Policlinico G Martino, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-2834","authenticated-orcid":false,"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[{"name":"BIOMORF Department, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Garcia-Ruiz","sequence":"additional","affiliation":[{"name":"Division of Cardiology, GIOMI Hospital, 98165 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-182X","authenticated-orcid":false,"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[{"name":"Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuele","family":"Soraci","sequence":"additional","affiliation":[{"name":"U.O.S. Emodinamica, Department of Medicine, Ospedale Barone Romeo di Patti, 98066 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Magliarditi","sequence":"additional","affiliation":[{"name":"U.O.S. Emodinamica, Department of Medicine, Ospedale Barone Romeo di Patti, 98066 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucio","family":"Teresi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Policlinico G Martino, 98125 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Nasso","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scipione","family":"Carerj","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Di Bella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Micari","sequence":"additional","affiliation":[{"name":"BIOMORF Department, University of Messina, 98122 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6031-2899","authenticated-orcid":false,"given":"Giuseppe","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"},{"name":"Division of Cardiology, IRCCS Hospital Galeazzi-Sant\u2019Ambrogio, 20157 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4244\/EIJY15M06_04","article-title":"Very High-Pressure Dilatation for Undilatable Coronary Lesions: Indications and Results with a New Dedicated Balloon","volume":"12","author":"Secco","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.jcin.2021.08.069","article-title":"Improving PCI Outcomes Using Postprocedural Physiology and Intravascular Imaging","volume":"14","author":"Ali","year":"2021","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on Myocardial Revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ccd.30791","article-title":"Ten-year Clinical Outcomes from a Randomized Trial Comparing New-generation Everolimus-eluting Stent versus First-generation Sirolimus-eluting Stent: Results from the RESET Extended Study","volume":"102","author":"Shiomi","year":"2023","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2017.06.022","article-title":"Everolimus Eluting Stent vs First Generation Drug-Eluting Stent in Primary Angioplasty: A Pooled Patient-Level Meta-Analysis of Randomized Trials","volume":"244","author":"Smits","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jacc.2005.11.018","article-title":"Relationship Between Patient\u2019s Risk Profile and Benefits in Mortality from Adjunctive Abciximab to Mechanical Revascularization for ST-Segment Elevation Myocardial Infarction: A Meta-Regression Analysis of Randomized Trials","volume":"47","author":"Suryapranata","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Silverio, A., Di Maio, M., Citro, R., Esposito, L., Iuliano, G., Bellino, M., Baldi, C., De Luca, G., Ciccarelli, M., and Vecchione, C. (2021). Cardiovascular Risk Factors and Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis of 45 Studies and 18,300 Patients. BMC Cardiovasc. Disord., 21.","DOI":"10.1186\/s12872-020-01816-3"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1406656","article-title":"Demographic and Epidemiologic Drivers of Global Cardiovascular Mortality","volume":"372","author":"Roth","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.2337\/dc12-1507","article-title":"Impact of Diabetes on Long-Term Outcome After Primary Angioplasty","volume":"36","author":"Dirksen","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jacasi.2023.03.014","article-title":"10 Years of SYNTAX","volume":"3","author":"Serruys","year":"2023","journal-title":"JACC Asia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jacc.2023.06.026","article-title":"Long-Term Outcomes of Cardiogenic Shock Complicating Myocardial Infarction","volume":"82","author":"Sterling","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2023.09.001","article-title":"Lipoprotein(a), Interleukin-6 Inhibitors, and Atherosclerotic Cardiovascular Disease: Is There an Association?","volume":"54","author":"Makris","year":"2023","journal-title":"Atheroscler. Plus"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/j.jacc.2019.07.043","article-title":"Epigenetic Modification in Coronary Atherosclerosis","volume":"74","author":"Rizzacasa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Novara Atherosclerosis Study Group (NAS), De Luca, G., Verdoia, M., Cassetti, E., Schaffer, A., Cavallino, C., Bolzani, V., and Marino, P. (2011). High Fibrinogen Level Is an Independent Predictor of Presence and Extent of Coronary Artery Disease among Italian Population. J. Thromb. Thrombolysis, 31, 458\u2013463.","DOI":"10.1007\/s11239-010-0531-z"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diabet.2015.01.001","article-title":"Impact of Diabetes on Neutrophil-to-Lymphocyte Ratio and Its Relationship to Coronary Artery Disease","volume":"41","author":"Verdoia","year":"2015","journal-title":"Diabetes Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention: The PCI-CURE Study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMoa2208275","article-title":"Polypill Strategy in Secondary Cardiovascular Prevention","volume":"387","author":"Castellano","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-Dose Aspirin for the Prevention of Atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine Diphosphate\u2013Induced Platelet Aggregation Is Associated with P2Y 12 Gene Sequence Variations in Healthy Subjects","volume":"108","author":"Fontana","year":"2003","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.jacc.2017.08.018","article-title":"Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI","volume":"70","author":"Giustino","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","first-page":"804","article-title":"Trade-off of Myocardial Infarction vs. Bleeding Types on Mortality after Acute Coronary Syndrome: Lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Randomized Trial","volume":"38","author":"Valgimigli","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/eurheartj\/ehx503","article-title":"Case-Based Implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease","volume":"39","author":"Collet","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4244\/EIJV11I1A11","article-title":"Dual Antiplatelet Therapy Duration after Coronary Stenting in Clinical Practice: Results of an EAPCI Survey","volume":"11","author":"Valgimigli","year":"2015","journal-title":"EuroIntervention"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s40265-017-0806-1","article-title":"Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies","volume":"77","author":"Costa","year":"2017","journal-title":"Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.21037\/cdt.2018.10.01","article-title":"The Optimal Duration of Dual Antiplatelet Therapy after Coronary Stent Implantation: To Go Too Far Is as Bad as to Fall Short","volume":"8","author":"Costa","year":"2018","journal-title":"Cardiovasc. Diagn. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining Strategies of Modulation of Antiplatelet Therapy in Patients with Coronary Artery Disease: A Consensus Document from the Academic Research Consortium","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e014457","DOI":"10.1161\/JAHA.119.014457","article-title":"Efficacy and Safety of High Potent P2Y 12 Inhibitors Prasugrel and Ticagrelor in Patients with Coronary Heart Disease Treated with Dual Antiplatelet Therapy: A Sex-Specific Systematic Review and Meta-Analysis","volume":"9","author":"Schreuder","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM199201303260506","article-title":"The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes","volume":"326","author":"Epstein","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12471-018-1113-5","article-title":"Optimal Duration of Dual Antiplatelet Therapy for Coronary Artery Disease","volume":"26","author":"Kikkert","year":"2018","journal-title":"Neth. Heart J."},{"key":"ref_37","first-page":"611","article-title":"Drug-Eluting vs Bare-Metal Stents in Primary Angioplasty: A Pooled Patient-Level Meta-Analysis of Randomized Trials","volume":"172","author":"Dirksen","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late Thrombosis in Drug-Eluting Coronary Stents after Discontinuation of Antiplatelet Therapy","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2006.03.042","article-title":"Pathology of Drug-Eluting Stents in Humans","volume":"48","author":"Joner","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/CIRCULATIONAHA.106.666800","article-title":"A Cause for Concern","volume":"115","author":"Camenzind","year":"2007","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejcts.2010.08.019","article-title":"Guidelines on Myocardial Revascularization","volume":"38","author":"Kolh","year":"2010","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"g6427","DOI":"10.1136\/bmj.g6427","article-title":"Effects of Cobalt-Chromium Everolimus Eluting Stents or Bare Metal Stent on Fatal and Non-Fatal Cardiovascular Events: Patient Level Meta-Analysis","volume":"349","author":"Valgimigli","year":"2014","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1093\/eurheartj\/ehu318","article-title":"Endeavour Zotarolimus-Eluting Stent Reduces Stent Thrombosis and Improves Clinical Outcomes Compared with Cypher Sirolimus-Eluting Stent: 4-Year Results of the PROTECT Randomized Trial","volume":"35","author":"Wijns","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding Avoidance Strategies in Percutaneous Coronary Intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvaa001","article-title":"Very Short vs. Long Dual Antiplatelet Therapy after Second Generation Drug-Eluting Stents in 35 785 Patients Undergoing Percutaneous Coronary Interventions: A Meta-Analysis of Randomized Controlled Trials","volume":"7","author":"Benenati","year":"2021","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1056\/NEJMoa067731","article-title":"Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents","volume":"356","author":"Mauri","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.CIR.0000140721.27004.4B","article-title":"Beyond Restenosis: Five-Year Clinical Outcomes from Second-Generation Coronary Stent Trials","volume":"110","author":"Cutlip","year":"2004","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A Prospective Natural-History Study of Coronary Atherosclerosis","volume":"364","author":"Stone","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJM199005313222201","article-title":"Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction","volume":"322","author":"Trip","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/01.CIR.93.2.229","article-title":"Platelet Function in Acute Myocardial Infarction Treated with Direct Angioplasty","volume":"93","author":"Gawaz","year":"1996","journal-title":"Circulation"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"66.e9","DOI":"10.1016\/j.ahj.2006.10.010","article-title":"A Comparison of Prasugrel and Clopidogrel Loading Doses on Platelet Function: Magnitude of Platelet Inhibition Is Related to Active Metabolite Formation","volume":"153","author":"Brandt","year":"2007","journal-title":"Am. Heart J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.amjmed.2014.12.007","article-title":"Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-Up","volume":"128","author":"Alnasser","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular Risk in Post-Myocardial Infarction Patients: Nationwide Real World Data Demonstrate the Importance of a Long-Term Perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2016.03.033","article-title":"Role of Stent Type and of Duration of Dual Antiplatelet Therapy in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Interventions. Is Bare Metal Stent Implantation Still a Justifiable Choice? A Post-Hoc Analysis of the All Comer PRODIGY Trial","volume":"212","author":"Crimi","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.jacc.2015.03.003","article-title":"Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients with and without Acute Myocardial Infarction","volume":"65","author":"Yeh","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jacc.2015.05.080","article-title":"Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration","volume":"66","author":"Costa","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_60","first-page":"390","article-title":"Long-Term Dual Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events in the Subgroup of Patients with Previous Myocardial Infarction: A Collaborative Meta-Analysis of Randomized Trials","volume":"37","author":"Udell","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2015.08.058","article-title":"Impact of Greater than 12-Month Dual Antiplatelet Therapy Duration on Mortality: Drug-Specific or a Class-Effect? A Meta-Analysis","volume":"201","author":"Costa","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ahj.2009.02.008","article-title":"Efficacy of Xience\/Promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) Trial: Study Design and Rationale of a Korean Multicenter Prospective Randomized Trial","volume":"157","author":"Park","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ahj.2016.01.015","article-title":"Impact of Proton Pump Inhibitors on Clinical Outcomes in Patients Treated with a 6- or 24-Month Dual-Antiplatelet Therapy Duration: Insights from the PROlonging Dual-Antiplatelet Treatment after Grading Stent-Induced Intimal Hyperplasia study Trial","volume":"174","author":"Gargiulo","year":"2016","journal-title":"Am. Heart J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijcard.2015.04.159","article-title":"Does Smoking Habit Affect the Randomized Comparison of 6 versus 24-Month Dual Antiplatelet Therapy Duration? Insights from the PRODIGY Trial","volume":"190","author":"Adamo","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/eurheartj\/ehv038","article-title":"Impact of Clinical Presentation on Ischaemic and Bleeding Outcomes in Patients Receiving 6- or 24-Month Duration of Dual-Antiplatelet Therapy after Stent Implantation: A Pre-Specified Analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment after Grading Stent-Induced Intimal Hyperplasia) Trial","volume":"36","author":"Costa","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final Results of the Randomised Evaluation of Short-Term Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Treated with a New-Generation Stent (REDUCE Trial)","volume":"15","author":"Damen","year":"2019","journal-title":"EuroIntervention"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e3530","DOI":"10.1002\/dmrr.3530","article-title":"Short-term Dual Antiplatelet Therapy in Diabetic Patients Admitted for Acute Coronary Syndrome Treated with a New-generation Drug-eluting Stent","volume":"38","author":"Vranken","year":"2022","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s11239-021-02439-x","article-title":"Gender Differences with Short-Term vs 12 Months Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Treated with the COMBO Dual Therapy Stent: 2-Years Follow-up Results of the REDUCE Trial","volume":"52","author":"Verdoia","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2021.02.006","article-title":"Impact of Age on the Comparison between Short-Term vs 12-Month Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome Treated with the COMBO Dual Therapy Stent: 2-Year Follow-up Results of the REDUCE Trial","volume":"321","author":"Kedhi","year":"2021","journal-title":"Atherosclerosis"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/eurheartj\/ehv053","article-title":"Duration of Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation: Will We Ever Reach a Consensus?","volume":"36","author":"Valgimigli","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/eurheartj\/ehab391","article-title":"Management of Acute Coronary Syndromes in Older Adults","volume":"43","author":"Morici","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2020.11.065","article-title":"Bleeding Risk Prediction in Elderly Patients Managed Invasively for Acute Coronary Syndromes: External Validation of the PRECISE-DAPT and PARIS Scores","volume":"328","author":"Montalto","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e002279","DOI":"10.1161\/CIRCINTERVENTIONS.114.002279","article-title":"Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus: Insights from a Patient-Level Pooled Analysis of SYNTAX, RESOLUTE, and LEADERS Trials","volume":"8","author":"Campos","year":"2015","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijcard.2016.02.085","article-title":"A Contemporary Risk Model for Predicting 30-Day Mortality Following Percutaneous Coronary Intervention in England and Wales","volume":"210","author":"McAllister","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4244\/EIJ-D-20-00885","article-title":"Antithrombotic Therapy after Percutaneous Coronary Intervention of Bifurcation Lesions","volume":"17","author":"Zimarino","year":"2021","journal-title":"EuroIntervention"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jcin.2019.01.212","article-title":"Characterization of the Individual Patient Risk After Percutaneous Coronary Intervention","volume":"12","author":"Giustino","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Caracciolo, A., Mazzone, P., Laterra, G., Garcia-Ruiz, V., Polimeni, A., Galasso, S., Saporito, F., Carerj, S., D\u2019Ascenzo, F., and Marquis-Gravel, G. (2019). Antithrombotic Therapy for Percutaneous Cardiovascular Interventions: From Coronary Artery Disease to Structural Heart Interventions. J. Clin. Med., 8.","DOI":"10.3390\/jcm8112016"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e1222","DOI":"10.4244\/EIJY15M08_04","article-title":"Left Main or Proximal Left Anterior Descending Coronary Artery Disease Location Identifies High-Risk Patients Deriving Potentially Greater Benefit from Prolonged Dual Antiplatelet Therapy Duration","volume":"11","author":"Costa","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","first-page":"3238","article-title":"Antithrombotic Therapy in the Elderly: Expert Position Paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/eurheartj\/ehac515","article-title":"Acute, Periprocedural and Longterm Antithrombotic Therapy in Older Adults","volume":"44","author":"Andreotti","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"De Servi, S., Landi, A., Savonitto, S., Morici, N., De Luca, L., Montalto, C., Crimi, G., De Rosa, R., and De Luca, G. (2023). Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field. J. Clin. Med., 12.","DOI":"10.3390\/jcm12052082"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Developed in Collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.115.016783","article-title":"Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study","volume":"133","author":"Meredith","year":"2016","journal-title":"Circulation"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in Ischemic Events with Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS\u2013TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients with Peripheral Artery Disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs Short Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention in Patients with or Without Peripheral Arterial Disease: A Subgroup Analysis of the PRODIGY Randomized Clinical Trial","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e002524","DOI":"10.1161\/JAHA.115.002524","article-title":"Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy","volume":"4","author":"Costa","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and Validation of the Predicting Bleeding Complications in Patients Undergoing Stent Implantation and Subsequent Dual Antiplatelet Therapy (PRECISE-DAPT) Score: A Pooled Analysis of Individual-Patient Datasets from Clinical Trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ahj.2023.02.011","article-title":"External Validation of Bleeding Risk Models for the Prediction of Long-Term Bleeding Risk in Patients with Established Cardiovascular Disease","volume":"260","author":"Castelijns","year":"2023","journal-title":"Am. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Munaf\u00f2, A.R., Montalto, C., Franzino, M., Pistelli, L., Di Bella, G., Ferlini, M., Leonardi, S., D\u2019Ascenzo, F., Gragnano, F., and Oreglia, J.A. (2023). External Validity of the PRECISE-DAPT Score in Patients Undergoing PCI: A Systematic Review and Meta-Analysis. Eur. Heart J.-Cardiovasc. Pharmacother., pvad063.","DOI":"10.1093\/ehjcvp\/pvad063"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2020.01.014","article-title":"A 4-Item PRECISE-DAPT Score for Dual Antiplatelet Therapy Duration Decision-Making","volume":"223","author":"Costa","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2021.11.015","article-title":"Validation of the Academic Research Consortium High Bleeding Risk Criteria in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of 10 Studies and 67,862 Patients","volume":"347","author":"Silverio","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2021.08.074","article-title":"Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI","volume":"78","author":"Valgimigli","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ahj.2020.09.019","article-title":"Design and Rationale of the XIENCE Short DAPT Clinical Program: An Assessment of the Safety of 3-Month and 1-Month DAPT in Patients at High Bleeding Risk Undergoing PCI with an Everolimus-Eluting Stent","volume":"231","author":"Valgimigli","year":"2021","journal-title":"Am. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual Antiplatelet Therapy Duration after Percutaneous Coronary Intervention in High Bleeding Risk: A Meta-Analysis of Randomized Trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_101","unstructured":"Han, Y. (2023, January 28). Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients\u2014OPT-BIRISK. Proceedings of the ESC Congress 2023\u2014Amsterdam, Online."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/eurheartj\/ehac294","article-title":"Great Debate: Triple Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting Should Be Limited to 1 Week","volume":"43","author":"Agewall","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus Aspirin versus Oral Anticoagulation for Atrial Fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): A Randomised Controlled Trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","article-title":"Risk of Bleeding in Patients with Acute Myocardial Infarction Treated with Different Combinations of Aspirin, Clopidogrel, and Vitamin K Antagonists in Denmark: A Retrospective Analysis of Nationwide Registry Data","volume":"374","author":"Hansen","year":"2009","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal Antithrombotic Regimens for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-Analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ehjcvp\/pvaa135","article-title":"Antithrombotic Therapy According to Baseline Bleeding Risk in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Applying the PRECISE-DAPT Score in RE-DUAL PCI","volume":"8","author":"Costa","year":"2022","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijcard.2019.12.054","article-title":"Double or Triple Antithrombotic Therapy after Coronary Stenting and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials","volume":"302","author":"Costa","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ccd.29192","article-title":"Antithrombotic Strategies in Patients Needing Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis","volume":"97","author":"Saglietto","year":"2021","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/ehjcvp\/pvac065","article-title":"Dual Antiplatelet Therapy Duration after Percutaneous Coronary Intervention in Patients with Indication to Oral Anticoagulant Therapy. A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Montalto","year":"2023","journal-title":"Eur. Heart J.-Cardiovasc. Pharmacother."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy after Coronary Revascularisation: Individual Patient Level Meta-Analysis of Randomised Controlled Trials","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.cjca.2019.12.013","article-title":"A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease","volume":"36","author":"Mehta","year":"2020","journal-title":"Can. J. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"(1996). A Randomised, Blinded, Trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). Lancet, 348, 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","article-title":"Monotherapy with a P2Y12 Inhibitor or Aspirin for Secondary Prevention in Patients with Established Atherosclerosis: A Systematic Review and Meta-Analysis","volume":"395","author":"Chiarito","year":"2020","journal-title":"Lancet"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1161\/CIRCULATIONAHA.122.062770","article-title":"Aspirin Versus Clopidogrel for Long-Term Maintenance Monotherapy after Percutaneous Coronary Intervention: The HOST-EXAM Extended Study","volume":"147","author":"Kang","year":"2023","journal-title":"Circulation"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events","volume":"82","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_120","unstructured":"Min, P. (2023, January 26). P2Y12 Inhibitor Monotherapy vs DAPT after PCI with BP-EES: The SHARE Randomized Clinical Trial. Proceedings of the ESC Congress 2023\u2014Amsterdam, Online."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus Aspirin for 1 Month, Followed by Ticagrelor Monotherapy for 23 Months vs Aspirin plus Clopidogrel or Ticagrelor for 12 Months, Followed by Aspirin Monotherapy for 12 Months after Implantation of a Drug-Eluting Stent: A Multicentre, Open-Label, Randomised Superiority Trial","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jcin.2020.06.023","article-title":"Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients with Stable CAD","volume":"13","author":"Kogame","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jcin.2023.05.035","article-title":"P2Y12 Inhibitor Monotherapy Combined with Colchicine Following PCI in ACS Patients","volume":"16","author":"Lee","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4244\/EIJ-D-22-00886","article-title":"Single Antiplatelet Therapy Directly after Percutaneous Coronary Intervention in Non-ST-Segment Elevation Acute Coronary Syndrome Patients: The OPTICA Study","volume":"19","author":"Claessen","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jcin.2023.06.033","article-title":"Aspirin-Free Strategy After ACS Implementing Colchicine","volume":"16","author":"Costa","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_126","unstructured":"(2023, January 26). Masahiro Natsuaki Short and Optimal Duration of Dual Antiplatelet Therapy after Everolimus-Eluting Cobalt-Chromium Stent-3\u2014STOPDAPT-3. Proceedings of the ESC Congress 2023\u2014Amsterdam, Online."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","article-title":"Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update","volume":"54","author":"Teng","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2796.2010.02299.x","article-title":"Antiplatelet Drug Interactions","volume":"268","author":"Mackenzie","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_130","first-page":"115","article-title":"Selective Serotonin Reuptake Inhibitors and Bleeding Risk after PCI. A Propensity Score Matching Study","volume":"4","author":"Ojeda","year":"2022","journal-title":"REC Interv. Cardiol. Engl. Ed."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00228-019-02777-z","article-title":"Concomitant Use of Drugs Known to Cause Interactions with Oral Antiplatelets\u2014Polypharmacy in Acute Coronary Syndrome Outpatients in Finland","volume":"76","author":"Prami","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCINTERVENTIONS.110.957829","article-title":"Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake: Results of a Prospective Randomized Crossover Study","volume":"3","author":"Ferreiro","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.thromres.2011.06.029","article-title":"Doubling the Dose of Clopidogrel Restores the Loss of Antiplatelet Effect Induced by Esomeprazole","volume":"128","author":"Moceri","year":"2011","journal-title":"Thromb. Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00228-008-0612-5","article-title":"SFINX\u2014A Drug-Drug Interaction Database Designed for Clinical Decision Support Systems","volume":"65","author":"Laine","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without Omeprazole in Coronary Artery Disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jama.2015.0809","article-title":"Association of NSAID Use with Risk of Bleeding and Cardiovascular Events in Patients Receiving Antithrombotic Therapy After Myocardial Infarction","volume":"313","author":"Gislason","year":"2015","journal-title":"JAMA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document from the Academic Research Consortium for High Bleeding Risk","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40262-018-0637-6","article-title":"Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites","volume":"57","author":"Marsousi","year":"2018","journal-title":"Clin. Pharmacokinet."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/22\/7144\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:24:37Z","timestamp":1760131477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/22\/7144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":138,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12227144"],"URL":"https:\/\/doi.org\/10.3390\/jcm12227144","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]}}}